BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclexta
Ayisha Sharma / endpoints - BeOne Medicines has clinched US accelerated approval for its drug sonrotoclax in a rare but aggressive form of blood cancer, where AbbVie and Genentech’s Venclexta is used off-label. The FDA greenlit ...
AI Summary: BeOne Medicines secured FDA approval for a next-generation BCL2 inhibitor, positioning the drug as a direct challenge to AbbVie/Roche’s Venclexta franchise. The move reshuffles competitive dynamics in hematology, potentially offering clinicians an alternative and setting the stage for market share battles and payer negotiations. Expect aggressive positioning and head-to-head data requests.
Related Stories
FDA clears Trodelvy alone and with Keytruda for first-line TNBC / 14 days
Datroway secures regulatory approvals in breast cancer across US and EU / 7 wks
FDA clears pivekimab sunirine (Decnupaz) as first BPDCN ADC / 6 wks
FDA to revisit Atara/Pierre Fabre cell therapy approval for rare lymphoma / 2 months
FDA advisory panel rejects camizestrant after SERENA‑6 results / 2 months
FDA greenlights datopotamab deruxtecan for metastatic TNBC / 14 days
FDA approves belzutifan (Welireg) plus pembrolizumab for adjuvant RCC / 21 days
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Trump Administration, Pharmaceuticals, Weight Loss, Long COVID and look for the RSS link.
StackHealth Time Machine